Inhibikase Therapeutics (IKT) Return on Sales (2020 - 2024)
Inhibikase Therapeutics (IKT) has 5 years of Return on Sales data on record, last reported at 200639.37% in Q3 2024.
- On a quarterly basis, Return on Sales fell 20063877.0% to 200639.37% in Q3 2024 year-over-year; TTM through Sep 2024 was 200639.37%, a 20063875.0% decrease, with the full-year FY2023 number at 0.77%, up 70.0% from a year prior.
- Return on Sales reached 200639.37% in Q3 2024 per IKT's latest filing, down from 2.39% in the prior quarter.
- Over the last five years, Return on Sales for IKT hit a ceiling of 0.02% in Q1 2021 and a floor of 200639.37% in Q3 2024.
- A 5-year average of 12880.09% and a median of 0.68% in 2022 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: surged 2525bps in 2022, then crashed -20063877bps in 2024.
- Tracing IKT's Return on Sales over 5 years: stood at 0.07% in 2020, then tumbled by -36487bps to 25.93% in 2021, then skyrocketed by 97bps to 0.68% in 2022, then tumbled by -6457080bps to 44035.66% in 2023, then crashed by -356bps to 200639.37% in 2024.
- Business Quant data shows Return on Sales for IKT at 200639.37% in Q3 2024, 2.39% in Q2 2024, and 1.03% in Q1 2024.